J. Safra Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

J. Safra Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-397	Closed	-$15.8K	–	648
2026 Q1	$15.8K	Buy	397 +298	+301%	+$7.62K	﹤0.01%	328
2025 Q4	$2.48K	Buy	+99	New	+$2.51K	﹤0.01%	530

J. Safra Asset Management's CNTA Position: Q2 2026 in Review

J. Safra Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 397 shares — an estimated $15.8K sold.

J. Safra Asset Management first reported a position in CNTA in Q4 2025 and held it in 2 quarters. The position peaked at $15.8K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

J. Safra Asset Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
J. Safra Asset Management sold 397 Centessa Pharmaceuticals shares in Q2 2026, an estimated $15.8K.
J. Safra Asset Management first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
J. Safra Asset Management's Centessa Pharmaceuticals position peaked at $15.8K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.